U.S. Bank’s new Business Essentials cards offer up to 3.5% cash back, aiming at small firms that pick cards for rewards.
U.S. Bank Launches Cards To Meet Small Business Rewards Demand
Browsing Category
General
224 posts
A Clearer Look At GLP-1 Availability And Out-of-Pocket Costs
Brand GLP-1s are off the FDA shortage list, but dose-level stockouts and cash prices ranging from $199 to over $1,000 per month persist across channels.
Will Elon Musk Post 160-179 Tweets From September 22 To September 29, 2026?
A Polymarket contract on whether Elon Musk posts 160–179 tweets from Sept. 22 to 29 is priced at 2% YES, with $101,000 in 24-hour volume.
Will Elon Musk Post 65-89 Tweets From September 26 To September 28, 2026?
A Polymarket contract on whether Elon Musk will post 65-89 tweets Sept 26-28, 2026 jumped to 47% YES on $107K volume. The trigger is unclear.
A Closer Look At IEP Negotiation Simulators For Parent Advocates
An IEP negotiation simulator is proposed as a meeting-preparation tool for parents, with a 40-family test suggested to assess its value.
Philip R. Lane: The Outlook For The Euro Area Economy
Search and coverage interest is surging around ECB Chief Economist Philip R. Lane’s ‘The Outlook for the Euro Area Economy’. The trigger remains unconfirmed.
How Founders Can Use Offer Builders To Support Fractional Executives
A new offer builder tool aims to help founders support executives transitioning to fractional roles, improving packaging, pricing, and client acquisition.
Food Recalls And Trends: Uninspected Beef, Pork, And Goat Under The Spotlight
Recent food recalls involving uninspected beef, pork, and goat highlight ongoing safety concerns. This report details confirmed facts and emerging issues.
Palisade Bio Receives FDA Clearance Of IND For PALI-2108 In Crohn’s Disease, Expanding Phase 2 Development Across IBD
Palisade Bio has received FDA clearance to proceed with Phase 2 trials of PALI-2108 for Crohn’s disease, advancing its development in inflammatory bowel disease.
Boris Vujčić: Interview With Reuters
Coverage interest is surging around a Boris Vujčić interview with Reuters. Content is unconfirmed, but ECB policy signals may be the draw.
